U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H20N6O.2C3H6O2
Molecular Weight 496.5588
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IMIDOCARB DIPROPIONATE

SMILES

CCC(O)=O.CCC(O)=O.O=C(NC1=CC=CC(=C1)C2=NCCN2)NC3=CC=CC(=C3)C4=NCCN4

InChI

InChIKey=AFGQXWSHYUHHNV-UHFFFAOYSA-N
InChI=1S/C19H20N6O.2C3H6O2/c26-19(24-15-5-1-3-13(11-15)17-20-7-8-21-17)25-16-6-2-4-14(12-16)18-22-9-10-23-18;2*1-2-3(4)5/h1-6,11-12H,7-10H2,(H,20,21)(H,22,23)(H2,24,25,26);2*2H2,1H3,(H,4,5)

HIDE SMILES / InChI
Molecular Formula C3H6O2
Molecular Weight 74.0785
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C19H20N6O
Molecular Weight 348.4017
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Imidocarb is a carbanilide derivative with antiprotozoal activity. It is usually administered as the dipropionate salt. Imidocarb is a drug sold under the brand name Imizol and is used to treat canine ehrlichiosis. wo mechanisms of action have been proposed: As the effect of imidocarb on Trypanosoma brucei is antagonized by excess polyamines, it is has been suggested that imidocarb interferes with their production and/or use. Imidocarb blocks the entry of inositol into erythrocytes containing Babesia, resulting in starvation of the parasite. It is generally accepted in that imidocarb has anticholinesterase activity.

Approval Year

1997
176
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8228
Inhibitor
8228
Inhibitor
8228
 590.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8360
Imizol

Approved Use

For the treatment of babesiosis in dogs with clinical signs and/or demonstrated Babesia organisms in the blood.

Launch Date

8.7886083E11
Curative
Approved
8360
IMIDOCARB

Approved Use

For treatment of babesiosis in cattle and horses

Launch Date

9.8867518E11
PubMed

PubMed

TitleDatePubMed
Cationic antitrypanosomal and other antimicrobial agents in the therapy of experimental Pneumocystis carinii pneumonia.
1988 Jun
Determination of whole blood cholinesterase in different animal species using specific substrates.
2001 Jun
Electron microscopic investigations on stages of dog piroplasms cultured in vitro: Asian isolates of Babesia gibsoni and strains of B. canis from France and Hungary.
2002 Jan
Residual effect of antibabesial drugs on the live redwater blood vaccines.
2002 Oct
Imidocarb, a potent anti-protozoan drug, up-regulates interleukin-10 production by murine macrophages.
2003 Sep 19
Identification of anti-babesial activity for four ethnoveterinary plants in vitro.
2005 Jun 10
Effective imidocarb dipropionate therapy for Babesia shortti in falcons.
2006 Feb 18
Pharmacokinetics and mammary elimination of imidocarb in sheep and goats.
2006 Jul
Flow cytometric evaluation of selected antimicrobial efficacy for clearance of Anaplasma marginale in short-term erythrocyte cultures.
2006 Jun
Clinicopathological changes and effect of imidocarb therapy in dogs experimentally infected with Babesia canis.
2006 Mar
Histological and ultrastructural studies of renal lesions in Babesia canis infected dogs treated with imidocarb.
2007 Dec
Therapeutic and prophylactic efficacy of imidocarb dipropionate on experimental Babesia ovis infection of lambs.
2007 Oct 21
[Dogs babesiosis--still actually problem].
2008
Canine vector-borne diseases in Brazil.
2008 Aug 8
Repeated high dose imidocarb dipropionate treatment did not eliminate Babesia caballi from naturally infected horses as determined by PCR-reverse line blot hybridization.
2008 Feb 14
An unusual form of canine babesiosis.
2008 Mar
Putative clinical piroplasmosis in a Burchell's zebra (Equus quagga burchelli).
2009 Dec
Detection of a large unnamed Babesia piroplasm originally identified in dogs in North Carolina in a dog with no history of travel to that state.
2009 Oct 1
Canine babesiosis in northern Portugal and molecular characterization of vector-borne co-infections.
2010 Apr 8
Haemotropic mycoplasmas: what's their real significance in cats?
2010 May
Patents

Patents

CN101214272A
3
CN105949127A
3
EP0305968
3
US20120129801
3

Sample Use Guides

In Vivo Use Guide
Use intramuscularly or subcutaneously at a rate of 6.6 mg/kg (3 mg/lb) body weight. Repeat the dose in two (2) weeks, for a total of two (2) treatments.
Route of Administration: Other
In Vitro Use Guide
The concentration of Imidocarb causing 50% inhibition of [3H]hypoxanthine incorporation (ID50 value) by Babesia bovis (Lismore and Samford isolates) cultured in vitro for Imidocarb was determined to be 3 ng/ml (8.6 nM).
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:24:44 UTC 2023
Edited
by admin
on Wed Jul 05 23:24:44 UTC 2023
Record UNII
ZSM1M03SHC
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
IMIDOCARB DIPROPIONATE
GREEN BOOK   MART.  
Common Name English
N,N'-BIS(3-(4,5-DIHYDRO-1H-IMIDAZOL-2-YL)PHENYL)UREA DIPROPIONATE
Systematic Name English
3,3'-DI-2-IMIDAZOLIN-2-YLCARBANILIDE DIPROPIONATE
Common Name English
IMIDOCARB DIPROPIONATE [GREEN BOOK]
Common Name English
IMIDOCARB DIPROPIONATE [MART.]
Common Name English
Classification Tree Code System Code
CFR 21 CFR 522.1156
Created by admin on Wed Jul 05 23:24:44 UTC 2023 , Edited by admin on Wed Jul 05 23:24:44 UTC 2023
CFR 21 CFR 522.1155
Created by admin on Wed Jul 05 23:24:44 UTC 2023 , Edited by admin on Wed Jul 05 23:24:44 UTC 2023
Code System Code Type Description
EPA CompTox
DTXSID4046604
Created by admin on Wed Jul 05 23:24:44 UTC 2023 , Edited by admin on Wed Jul 05 23:24:44 UTC 2023
PRIMARY
WIKIPEDIA
Imidocarb dipropionate
Created by admin on Wed Jul 05 23:24:44 UTC 2023 , Edited by admin on Wed Jul 05 23:24:44 UTC 2023
PRIMARY
RXCUI
1740238
Created by admin on Wed Jul 05 23:24:44 UTC 2023 , Edited by admin on Wed Jul 05 23:24:44 UTC 2023
PRIMARY
DAILYMED
ZSM1M03SHC
Created by admin on Wed Jul 05 23:24:44 UTC 2023 , Edited by admin on Wed Jul 05 23:24:44 UTC 2023
PRIMARY
PUBCHEM
9983292
Created by admin on Wed Jul 05 23:24:44 UTC 2023 , Edited by admin on Wed Jul 05 23:24:44 UTC 2023
PRIMARY
ECHA (EC/EINECS)
259-791-8
Created by admin on Wed Jul 05 23:24:44 UTC 2023 , Edited by admin on Wed Jul 05 23:24:44 UTC 2023
PRIMARY
NCI_THESAURUS
C76007
Created by admin on Wed Jul 05 23:24:44 UTC 2023 , Edited by admin on Wed Jul 05 23:24:44 UTC 2023
PRIMARY
CAS
55750-06-6
Created by admin on Wed Jul 05 23:24:44 UTC 2023 , Edited by admin on Wed Jul 05 23:24:44 UTC 2023
PRIMARY
SMS_ID
300000023751
Created by admin on Wed Jul 05 23:24:44 UTC 2023 , Edited by admin on Wed Jul 05 23:24:44 UTC 2023
PRIMARY
FDA UNII
ZSM1M03SHC
Created by admin on Wed Jul 05 23:24:44 UTC 2023 , Edited by admin on Wed Jul 05 23:24:44 UTC 2023
PRIMARY
MESH
C031719
Created by admin on Wed Jul 05 23:24:44 UTC 2023 , Edited by admin on Wed Jul 05 23:24:44 UTC 2023
PRIMARY
DRUG BANK
DBSALT001684
Created by admin on Wed Jul 05 23:24:44 UTC 2023 , Edited by admin on Wed Jul 05 23:24:44 UTC 2023
PRIMARY
Related Record Type Details
Structure of IMIDOCARB
PARENT -> SALT/SOLVATE
Structure of Propionic acid
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of IMIDOCARB
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966